Immunoglobulin E specific for Phleum pratense allergen 1 (Phl p 1) (IgE Phl p 1)

Immunoglobulin E (IgE) specific for Phleum pratense allergen 1 (Phl p 1) is a central mediator in the pathogenesis of Timothy grass pollen allergy, a major cause of seasonal allergic rhinitis and asthma (Valenta et al., 1992, PubMed: 1374741). Phl p 1 is a 27-kDa glycoprotein belonging to the beta-expansin family and is recognized as a major allergen due to its high prevalence of IgE-binding in sensitized individuals (WHO/IUIS Allergen Nomenclature). These specific IgE antibodies circulate and bind to high-affinity FcεRI receptors on mast cells and basophils; subsequent exposure to Phl p 1 causes receptor cross-linking and the release of inflammatory mediators like histamine (Galli et al., 2008, Nature). Therapeutic interventions include the monoclonal antibody Omalizumab, which sequesters free IgE to prevent its binding to effector cells (National Center for Biotechnology Information, PubChem). Additionally, allergen-specific immunotherapy (AIT) utilizes Timothy grass extracts to induce immune tolerance, often characterized by a reduction in specific IgE and an increase in protective IgG4 antibodies (Akdis & Akdis, 2014, Nature Reviews Drug Discovery). Component-resolved diagnosis (CRD) using Phl p 1-specific IgE levels is essential for distinguishing primary grass sensitization from cross-reactivity with other pollen types (Sastre, 2010, Clinical & Experimental Allergy).

Other names

Anti-Phl p 1 IgETimothy grass pollen allergen Phl p 1-specific IgEsIgE Phl p 1Phl p 1-specific IgE

Anti-IgE monoclonal antibodies like Omalizumab bind to the Cε3 domain of free IgE, preventing its interaction with high-affinity FcεRI receptors on mast cells and basophils (National Center for Biotechnology Information, PubChem). Allergen-specific immunotherapy (AIT) involves the administration of Phl p 1 allergens to induce peripheral T-cell tolerance and promote the production of "blocking" IgG4 antibodies that compete with IgE for allergen binding (Akdis & Akdis, 2014, Nature Reviews Drug Discovery).